The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B

Li-Kun Zhong, Guo Zhang, Shuang-Yan Luo, Wu Yin, Huai-Yu Song, Li-Kun Zhong, Guo Zhang, Shuang-Yan Luo, Wu Yin, Huai-Yu Song

Abstract

Objective: To investigate the value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B (CHB).

Methods: A total of 158 CHB patients who underwent liver biopsy in our hospital were included, and the clinical characteristics of these patients were retrospectively analyzed. The diagnostic values of platelet count, aspartate aminotransferase-to-platelet ratio index (APRI), and the fibrosis index based on four factors (FIB-4) for significant fibrosis (F ≥ 2) and early cirrhosis (F = 4) stages in CHB patients were assessed by the use of receiver operating characteristic (ROC) analysis.

Results: The median (F0: 221.0; F1: 210.0; F2: 188.0; F3: 171.0; and F4: 155.5) and mean rank (F0: 120.4; F1: 100.1; F2: 82.2; F3: 67.9; and F4: 49.5) of platelet count decreased along the aggravation of fibrosis (F0-F4). The areas under the ROC curve for the platelet count in diagnosis of significant fibrosis stage was 0.70, which had no significant difference with FIB-4 (0.73) and APRI (0.68) in diagnostic efficacy (P = .428). The areas under the ROC curve of platelet count in diagnosis of early cirrhosis were 0.72, which had no significant difference with FIB-4 (0.76) and APRI (0.68) (P = .094).

Conclusion: The platelet count, as a simple and non-invasive index, could evaluate the degree of liver fibrosis in CHB individuals. At the same time, the diagnostic efficiency of platelet count to evaluate the significant liver fibrosis and early cirrhosis is comparable to FIB-4 and APRI.

Keywords: chronic hepatitis B; liver cirrhosis; liver fibrosis; platelet count.

© 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
Area under ROC curves of PLT, APRI, and FIB‐4 for the diagnosis of hepatic fibrosis (F ≥ 2; n = 158). APRI, aspartate aminotransferase‐to‐platelet ratio index; FIB‐4, the fibrosis index based on four factors; PLT, platelet count
Figure 2
Figure 2
Area under ROC curves of PLT, APRI, and FIB‐4 for the diagnosis of liver cirrhosis (F = 4; n = 158). APRI, aspartate aminotransferase‐to‐platelet ratio index; FIB‐4, the fibrosis index based on four factors; PLT, platelet count

References

    1. WHO Organization . Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: WHO Organization; 2015.
    1. Ganem D, Prince AM. Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med. 2004;350(11):1118‐1129.
    1. Kim KH, Shin HJ, Kim K, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology. 2007;132(5):1955‐1967.
    1. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis‐4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta‐analysis. Hepatology. 2015;61(1):292‐302.
    1. Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB‐4 scoring systems for non‐invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64(4):773‐780.
    1. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver Disease . Liver biopsy. Hepatology. 2009;49(3):1017‐1044.
    1. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518‐526.
    1. Vallet‐Pichard A, Mallet V, Nalpas B, et al. FIB‐ 4: an inexpensive and accurate marker of fibrosis in HCV infection: comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32‐36.
    1. Holmberg SD, Lu M, Rupp LB, et al. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis. 2013;57(2):240‐246.
    1. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317‐1325.
    1. Brewer DB. Max Schultze (1865), G. Bizzozero (1882) and the discovery of the platelet. Br J Haematol. 2006;133(3):251‐258.
    1. Aiolfi R, Sitia G. Chronic hepatitis B: role of anti‐platelet therapy in inflammation control. Cell Mol Immunol. 2015;12(3):264‐268.
    1. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011;105(Suppl 1):S13‐33.
    1. Ripoche J. Blood platelets and inflammation: their relationship with liver and digestive diseases. Clin Res Hepatol Gastroenterol. 2011;35(5):353‐357.
    1. Balaphas A, Meyer J, Sadoul K, et al. Platelets and platelet‐derived extracellular vesicles in liver physiology and disease. Hepatol Commun. 2019;3(7):855‐866.
    1. Peck‐Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017;37(6):778‐793.
    1. Chauhan A, Adams DH, Watson SP, Lalor PF. Platelets: no longer bystanders in liver disease. Hepatology. 2016;64(5):1774‐1784.
    1. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289‐293.
    1. Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. J Hepatol. 2003;38(2):223‐229.
    1. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053‐2063.
    1. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200‐207.
    1. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94(4):1018‐1022.
    1. Shukla A, Kapileswar S, Gogtay N, et al. Simple biochemical parameters and a novel score correlate with absence of fibrosis in patients with nonalcoholic fatty liver disease. Indian J Gastroenterol. 2015;34(4):281‐285.
    1. Li Q, Lu C, Li W, Huang Y, Chen L. The gamma‐glutamyl transpeptidase to platelet ratio for non‐invasive assessment of liver fibrosis in patients with chronic hepatitis B and non‐alcoholic fatty liver disease. Oncotarget. 2017;8(17):28641‐28649.
    1. Ophir J, Cespedes I, Ponnekanti H, Yazdi Y, Li X. Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrasonic Imaging. 1991;13(2):111‐134.
    1. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55(3):403‐408.
    1. Sebastiani G, Halfon P, Castera L, et al. Comparison of three algorithms of non‐invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther. 2012;35(1):92‐104.
    1. Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2.
    1. Fierbinteanu‐Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol. 2010;16(38):4784‐4791.
    1. Watanabe M, Murata S, Hashimoto I, et al. Platelets contribute to the reduction of liver fibrosis in mice. J Gastroenterol Hepatol. 2009;24(1):78‐89.
    1. Murata S, Hashimoto I, Nakano Y, Myronovych A, Watanabe M, Ohkohchi N. Single administration of thrombopoietin prevents progression of liver fibrosis and promotes liver regeneration after partial hepatectomy in cirrhotic rats. Ann Surg. 2008;248(5):821‐828.
    1. Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration. World J Gastroenterol. 2017;23(18):3228‐3239.
    1. Kurokawa T, Zheng YW, Ohkohchi N. Novel functions of platelets in the liver. J Gastroenterol Hepatol. 2016;31(4):745‐751.
    1. Ohta T, Sakaguchi K, Fujiwara A, et al. Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama. 2006;60(2):77‐84.
    1. Buckley MF, James JW, Brown DE, et al. A novel approach to the assessment of variations in the human platelet count. Thromb Haemost. 2000;83(3):480‐484.
    1. Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000‐1007.
    1. Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma. Cancer. 2006;107(9):2212‐2222.
    1. Iida H, Kaibori M, Matsui K, Ishizaki M, Kon M. Ratio of mean platelet volume to platelet count is a potential surrogate marker predicting liver cirrhosis. World J Hepatol. 2018;10(1):82‐87.
    1. El Serafy MA, Kassem AM, Omar H, Mahfouz MS, El Said EL Raziky M. APRI test and hyaluronic acid as non‐invasive diagnostic tools for post HCV liver fibrosis: systematic review and meta‐analysis. Arab J Gastroenterol. 2017;18(2):51‐57.
    1. Ragazzo TG, Paranagua‐Vezozzo D, Lima FR, et al. Accuracy of transient elastography‐FibroScan(R), acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB‐4 index compared with liver biopsy in patients with chronic hepatitis C. Clinics. 2017;72(9):516‐525.
    1. Yue W, Li Y, Geng J, Wang P, Zhang L. Aspartate aminotransferase to platelet ratio can reduce the need for transient elastography in Chinese patients with chronic hepatitis B. Medicine. 2019;98(49):e18038.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit